LRIG1 Antibody

說明書

中文名稱：

LRIG1兔多克隆抗體
貨號：

CSB-PA850317ESR1HU
規格：

￥440
圖片：
Immunohistochemistry of paraffin-embedded human brain tissue using CSB-PA850317ESR1HU at dilution of 1:100

Immunohistochemistry of paraffin-embedded human glioma using CSB-PA850317ESR1HU at dilution of 1:100
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) LRIG1 Polyclonal antibody
Uniprot No.：

Q96JA1
基因名：

LRIG1
別名：

Leucine rich repeat protein antibody; Leucine rich repeat protein LRIG1 antibody; leucine rich repeats and immunoglobulin like domains 1 antibody; Leucine-rich repeats and immunoglobulin-like domains protein 1 antibody; leucine-rich repeats- and immunoglobulin-like domains-cotnaining protein 1 antibody; LIG 1 antibody; LIG-1 antibody; LIG1 antibody; Lrig1 antibody; LRIG1_HUMAN antibody; Ortholog of mouse integral membrane glycoprotein LIG 1 antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human Leucine-rich repeats and immunoglobulin-like domains protein 1 protein (35-220AA)
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

Antigen Affinity Purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
產品提供形式：

Liquid
應用范圍：

ELISA, IHC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:20-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Acts as a feedback negative regulator of signaling by receptor tyrosine kinases, through a mechanism that involves enhancement of receptor ubiquitination and accelerated intracellular degradation.
基因功能參考文獻：
1. MiR-183 overexpression promoted radioresistance of glioblastoma via down-regulating LRIG1 and increasing the activity of EFGR/Akt. PMID: 29793318
2. LRIG1 is a negative regulator of RET2A and RET2B and is also downregulated in papillary and medullary thyroid carcinoma PMID: 29436694
3. LRIG1 expression in human GC tissues is inversely correlated with miR-20a and EGFR. PMID: 29450946
4. Role of LRIG1 in cancer [review] PMID: 27628597
5. LRIG1 expression may represent a barrier to EMT PMID: 26387542
6. LRIG1 role in the atrophic epidermis PMID: 28099467
7. Downregulation of LRIG1 expression in oral verrucous carcinoma tissue is reported. PMID: 27509922
8. LRIG1, as a negative mediated gene of tumor, can inhibit biological function of PAs via inhibiting PI3K/AKT and Ras/Raf/ERK pathways, and it might be a new target for gene therapy ofPituitary adenomas PMID: 27465333
9. LRIG1 and Fascin-1 were differently expressed in cancer and normal lung tissue in patients with NSCLC, which could be a biomarker for mediastinal lymph node metastasis in NSCLC patients. PMID: 28230028
10. Results suggest that the LRIG1could negatively control MRP-1 and the apoptosis to improve the sensitivity of VP16-related chemotherapy. PMID: 27183435
11. ERa-dependent expression of LRIG1 dampens ErbB3 signaling in luminal breast cancer cells, and by blocking ERa activity with fulvestrant, LRIG1 is decreased thus permitting ErbB3 accumulation, enhanced ErbB3 signaling to cell survival pathways PMID: 26148232
12. These findings demonstrate that LRIG1 is an independent prognostic factor in patients with non-small cell lung cancer PMID: 25813475
13. LRIG1 expression was associated with pathological type, differentiation status, and stage of Non-small Cell Lung Cancer. The result showed that LRIG1 was an independent prognostic factor for OS of NSCLC patients. PMID: 26632716
14. The inhibitory effects of LRIG1 are most likely mediated by suppression of the EGFR/PI3K/AKT pathway and epithelial-mesenchymal transition (EMT) process. PMID: 25860915
15. LRIG1 can enhance chemosensitivity in glioblastoma by inhibition of BCL-2 and MnSOD PMID: 25449296
16. Results showed that leucine-rich repeats and immunoglobulin-like domains can reverse multidrug resistance in glioblastoma, by negatively regulating epidermal growth factor receptor. PMID: 25801120
17. MiR-20a mediated temozolomide-resistance in glioblastoma cells through negatively regulating LRIG1 expression. PMID: 25960225
18. Based on these results, we concluded that the upregulation of LRIG1 expression inhibited the EGFR signaling pathway, activated the mitochondrial pathway of apoptosis and eventually increased the sensitivity of bladder cancer cells to CDDP. PMID: 25695283
19. a subset of human duodenal tumors exhibited features of LRIG1(-/-) adenomas, including loss of LRIG1, gastric metaplasia (MUCIN5AC and MUCIN6), and increased amphiregulin and Egfr activity. PMID: 25794708
20. LRIG1 is frequently methylated in human CRC and consequent mRNA and protein downregulation may contribute to tumor growth by activating EGFR/AKT signaling PMID: 26159916
21. findings indicate that downregulation of LRIG1 is possibly a novel potential marker of transformation and tumorigenesis in OSSN cases. PMID: 24709893
22. LRIG1 evolved in bladder cancer as a rare feedback negative attenuator of EGFR. PMID: 24314030
23. These findings suggested that LRIG1-targeting siRNA can exert a dramatically inhibitory effect on RNA transcription and protein expression of LRIG1. PMID: 22528225
24. Loss of LRIG1 was independently associated with risk of any relapse. PMID: 24879564
25. USP8 is involved in deubiquitination of LRIG1, influencing the efficiency of Met degradation. PMID: 24828152
26. LRIG1 immunoreactivity could be a clinically important prognostic marker in HPV-associated oropharyngeal cancer. PMID: 24548859
27. LRIG1 downregulation in cancer cells enhances EGFR-MAPK-SPHK1 signaling and ECM remodeling activity, leading to malignant phenotypes of head and neck cancers PMID: 23624915
28. LRIG1 mediates degradation of Met by SAIT301 and this degradation does not require Met activation. PMID: 23208509
29. Downregulation of LRIG1 expression promotes the aggressive properties of glioma cells via EGFR/Akt/c-Myc activation. PMID: 23124613
30. Data indicate that Lrig3 opposes Lrig1 negative regulatory action and enhances ErbB receptors ERBB2, ERBB3 and ERBB4 stability. PMID: 23723069
31. LRIG1 inhibits EGFR expression and the downstream signaling activation, interferes with Bcl-2/Topo-2 expressions and eventually sensitizes glioma cells to TMZ PMID: 23850692
32. High LRIG1 expression is associated with cervical adenocarcinoma progression. PMID: 23165628
33. These findings suggest that upregulation of LRIG1 expression enhances the CDDP sensitivity in the glioma cell line U251. PMID: 23581227
34. LRIG1 Loss of heterozygosity (LOH) is frequent across cancers and its loss is an early event in the development of human squamous carcinomas. PMID: 23208928
35. This study revealed that the previously described up-regulation of EGFR and down-regulation of ERBB4 occurred in all analyzed renal cell carcinoma types, whereas down-regulation of ERBB2 and LRIG1 was only present in clear cell renal cell carcinoma. PMID: 22554477
36. Cytoplasmic expression of LRIG1 is associated with meningiomas. PMID: 22484910
37. Observations suggest the tumor suppressor function of LRIG1 is lost in a subset of colorectal cancers. PMID: 22464327
38. our findings show that both upregulation of RTK signaling and attenuated TNFalpha expression caused by LRIG1 downregulation confers resistance to Smac mimetics PMID: 22241084
39. ErbB2 activation antagonizes ERalpha-driven Lrig1 expression, providing a mechanistic explanation for Lrig1 loss in ErbB2-positive breast cancer. This work provides strong evidence for a growth-inhibitory role for Lrig1 in breast cancer. PMID: 21821674
40. LRIG1 and LRIG2 expressions were seen in precancerous cervical epithelium and found to increase with increasing grade. PMID: 21632100
41. LRIG1-transduced cells treated with cisplatin had more severe DNA damage, cellular apoptosis, growth inhibition and reversal of invasion PMID: 21431282
42. LRIG1 was a marker for good prognosis after prostatectomy, which might be due to its growth inhibiting properties PMID: 21128282
43. the LRIG1 ectodomain can be proteolytically shed and can function as a non-cell-autonomous regulator of growth factor signaling PMID: 21087604
44. ERBB2 and LRIG1 copy number is increased in breast cancer PMID: 19490591
45. Down-regulation of LIG-1 is associated with cancer PMID: 12234026
46. Results demonstrate that LRIG1 is an integral cell-surface membrane protein that is expressed by specific cells in various human tissues and that its 143-kDa form might be cleaved into 111-kDa and 32-kDa fragments. PMID: 12684867
47. downregulation of LRIG1 is associated with renal cell carcinoma PMID: 14520461
48. LRIG1 evolved in mammals as a feedback negative attenuator of signaling by receptor tyrosine kinases PMID: 15282549
49. LRIG1-mediated receptor ubiquitination and degradation may contribute to the suppression of ErbB receptor function PMID: 15345710
50. A breast cancer linked gene is located within an amplicon containing the LRIG1 locus at 3p14.3. PMID: 16168117
顯示更多

收起更多
亞細胞定位：

Cell membrane; Single-pass type I membrane protein.
組織特異性：

Widely expressed.
數據庫鏈接：

HGNC: 17360

OMIM: 608868

KEGG: hsa:26018

STRING: 9606.ENSP00000273261

UniGene: Hs.518055

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human